One patent has been awarded to the company’s Recall-Vax technology and the second patent has been granted for IN-N01.
Recall-Vax is an active vaccine intended to generate highly specific antibodies against beta amyloid in serum of patients.
IN-N01 is made through the company’s Antisenilin technology platform, which has similar specificity for the beta amyloid toxin as does Bapineuzumab.
According to the company, the move would expand its Japanese patent portfolio.
The first patent was awarded in 2006 to the company’s Antisenilin Alzheimer’s monoclonal antibody technology.